A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Geron Corp stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 41,025 shares of GERN stock, worth $143,177. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,025
Previous 33,025 24.22%
Holding current value
$143,177
Previous $140,000 32.86%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$4.17 - $4.99 $33,360 - $39,920
8,000 Added 24.22%
41,025 $186,000
Q2 2024

Jul 19, 2024

SELL
$3.1 - $5.09 $23,801 - $39,081
-7,678 Reduced 18.86%
33,025 $140,000
Q1 2024

Apr 22, 2024

BUY
$1.75 - $3.44 $17,136 - $33,684
9,792 Added 31.68%
40,703 $134,000
Q4 2023

Jan 16, 2024

BUY
$1.74 - $2.31 $3,915 - $5,197
2,250 Added 7.85%
30,911 $65,000
Q3 2023

Oct 24, 2023

SELL
$2.11 - $3.28 $42,094 - $65,435
-19,950 Reduced 41.04%
28,661 $60,000
Q1 2023

Apr 14, 2023

SELL
$2.14 - $3.4 $76,719 - $121,890
-35,850 Reduced 42.45%
48,611 $105,000
Q4 2022

Feb 08, 2023

SELL
$2.03 - $2.42 $1,398 - $1,667
-689 Reduced 0.81%
84,461 $204,000
Q3 2022

Oct 25, 2022

SELL
$1.67 - $2.94 $2,505 - $4,410
-1,500 Reduced 1.73%
85,150 $199,000
Q2 2022

Aug 12, 2022

BUY
$1.19 - $1.65 $1,785 - $2,475
1,500 Added 1.76%
86,650 $134,000
Q1 2022

May 11, 2022

SELL
$0.99 - $1.6 $9,563 - $15,456
-9,660 Reduced 10.19%
85,150 $116,000
Q4 2021

Feb 08, 2022

SELL
$1.22 - $1.72 $3,660 - $5,160
-3,000 Reduced 3.07%
94,810 $116,000
Q3 2021

Nov 02, 2021

SELL
$1.2 - $1.5 $120 - $150
-100 Reduced 0.1%
97,810 $134,000
Q2 2021

Aug 11, 2021

SELL
$1.25 - $1.83 $23,081 - $33,790
-18,465 Reduced 15.87%
97,910 $138,000
Q1 2021

May 14, 2021

BUY
$1.52 - $2.1 $3,800 - $5,250
2,500 Added 2.2%
116,375 $184,000
Q4 2020

Feb 12, 2021

BUY
$1.55 - $2.05 $775 - $1,025
500 Added 0.44%
113,875 $181,000
Q3 2020

Nov 04, 2020

BUY
$1.59 - $2.19 $2,385 - $3,285
1,500 Added 1.34%
113,375 $197,000
Q2 2020

Jul 17, 2020

BUY
$1.05 - $2.18 $16,800 - $34,880
16,000 Added 16.69%
111,875 $244,000
Q1 2020

Apr 21, 2020

BUY
$0.89 - $1.49 $3,471 - $5,811
3,900 Added 4.24%
95,875 $114,000
Q4 2019

Feb 12, 2020

SELL
$1.27 - $1.54 $5,918 - $7,176
-4,660 Reduced 4.82%
91,975 $125,000
Q3 2019

Nov 07, 2019

SELL
$1.15 - $1.59 $1,150 - $1,590
-1,000 Reduced 1.02%
96,635 $129,000
Q2 2019

Aug 06, 2019

BUY
$1.37 - $2.02 $6,987 - $10,302
5,100 Added 5.51%
97,635 $138,000
Q1 2019

May 06, 2019

SELL
$1.01 - $1.83 $258 - $468
-256 Reduced 0.28%
92,535 $154,000
Q4 2018

Feb 11, 2019

SELL
$0.98 - $1.85 $10,265 - $19,378
-10,475 Reduced 10.14%
92,791 $93,000
Q3 2018

Nov 14, 2018

BUY
$1.76 - $6.38 $5,808 - $21,054
3,300 Added 3.3%
103,266 $182,000
Q2 2018

Jul 30, 2018

BUY
$3.29 - $4.82 $7,238 - $10,604
2,200 Added 2.25%
99,966 $343,000
Q1 2018

Apr 16, 2018

BUY
$1.81 - $5.98 $22,896 - $75,647
12,650 Added 14.86%
97,766 $416,000
Q4 2017

Feb 09, 2018

BUY
$1.8 - $2.32 $4,842 - $6,240
2,690 Added 3.26%
85,116 $153,000
Q3 2017

Oct 26, 2017

BUY
$1.99 - $2.65 $48,496 - $64,580
24,370 Added 41.98%
82,426 $180,000
Q2 2017

Aug 15, 2017

BUY
N/A
58,056
58,056 $161,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.32B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.